Post-TNFalpha
| PHA Biologicals |
| Pentoxyfylline |
etanercept, infliximab, adalimumab
32278362 2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
32382744 2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.
32473011 2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.
32436460 2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
32554621 2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.
32553760 2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.
C7334116 2020. Etanercept/methotrexate: COVID-19: case report.
32680535 2020. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series.
33036639 2020. Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.
33294881 2020. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19.
33004419 2020. Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community.
C7648207 2020. Adalimumab/anakinra/dexamethasone: COVID-19 infection cytomegalovirus reactivation and off-label use: case report.
